Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sitagliptin

FDA-approved product (tablet, oral), marketed as Zituvio, Brynovin, Januvia and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sitagliptin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Hyperlipidemia
  • Myocardial infarction
  • Stroke
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
FDA pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sitagliptin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sitagliptin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

    NCT03076112 · start 2017-04-25

    Registered record
    Registry ID
    NCT03076112
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ipragliflozin; Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-04-25
    Completion
    2022-08-31
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionIpragliflozin; Sitagliptin
    PhasePhase 3
    Registry statusCompleted

  • Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

    NCT03122041 · start 2016-08

    Registered record
    Registry ID
    NCT03122041
    Conditions
    PCOS
    Interventions
    Sitagliptin; Lifestyle intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-08
    Completion
    2016-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS
    InterventionSitagliptin; Lifestyle intervention
    PhasePhase 4
    Registry statusCompleted

  • Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

    NCT02577016 · start 2015-11-05

    Registered record
    Registry ID
    NCT02577016
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Sitagliptin; Placebo; Ipragliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-05
    Completion
    2016-11-18
    Enrolment
    141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSitagliptin; Placebo; Ipragliflozin
    PhasePhase 3
    Registry statusCompleted

  • Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

    NCT02373865 · start 2015-09

    Registered record
    Registry ID
    NCT02373865
    Conditions
    Diabetes Mellitus Type 2
    Interventions
    Sitagliptin; Glimepiride; Sitagliptin-Placebo; Glimepiride-Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2017-01
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus Type 2
    InterventionSitagliptin; Glimepiride; Sitagliptin-Placebo; Glimepiride-Placebo
    PhasePhase 4
    Registry statusTerminated

  • Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus

    NCT02444364 · start 2015-05

    Registered record
    Registry ID
    NCT02444364
    Conditions
    Type 2 Diabetes
    Interventions
    Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2015-05
    Completion
    2016-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionSitagliptin
    PhaseEarly phase 1
    Registry statusWithdrawn

  • Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

    NCT02330406 · start 2015-04

    Registered record
    Registry ID
    NCT02330406
    Conditions
    Dipeptidyl-Peptidase 4 Inhibitors; LDL Cholesterol; Glycosylated Hemoglobin; Diabetes Mellitus; Coronary Disease
    Interventions
    Anagliptin; Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-04
    Completion
    2019-03
    Enrolment
    353

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDipeptidyl-Peptidase 4 Inhibitors; LDL Cholesterol; Glycosylated Hemoglobin; Diabetes Mellitus +1 more
    InterventionAnagliptin; Sitagliptin
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

    NCT02318693 · start 2015-02-04

    Registered record
    Registry ID
    NCT02318693
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Sitagliptin; Glibenclamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-04
    Completion
    2015-12-15
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSitagliptin; Glibenclamide
    PhasePhase 4
    Registry statusCompleted

  • Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop

    NCT02328040 · start 2014-09

    Registered record
    Registry ID
    NCT02328040
    Conditions
    Diabetes Mellitus, Type 1
    Interventions
    Placebo and Insulin monotherapy via CL; Sitagliptin and insulin/novolog via CL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09
    Completion
    2016-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 1
    InterventionPlacebo and Insulin monotherapy via CL; Sitagliptin and insulin/novolog via CL
    PhasePhase 1
    Registry statusCompleted

  • Sitagliptin and Brown Adipose Tissue

    NCT02294084 · start 2014-03

    Registered record
    Registry ID
    NCT02294084
    Conditions
    Neoplasms, Adipose Tissue
    Interventions
    Sitagliptin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-03
    Completion
    2016-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms, Adipose Tissue
    InterventionSitagliptin; placebo
    PhasePhase 4
    Registry statusCompleted

  • Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

    NCT01856907 · start 2013-09-28

    Registered record
    Registry ID
    NCT01856907
    Conditions
    Disorder of Glucose Regulation
    Interventions
    Sitagliptin-Metformin; Metformin; Placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09-28
    Completion
    2017-09-28
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisorder of Glucose Regulation
    InterventionSitagliptin-Metformin; Metformin; Placebo pill
    PhasePhase 4
    Registry statusCompleted

  • Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

    NCT01845831 · start 2013-08

    Registered record
    Registry ID
    NCT01845831
    Conditions
    Type 2 Diabetes
    Interventions
    Sitagliptin; Basal Bolus; Metformin and Sitagliptin; Glargine; Glargine 50%; Glargine 80%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-08
    Completion
    2016-04
    Enrolment
    292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionSitagliptin; Basal Bolus; Metformin and Sitagliptin; Glargine +2 more
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

    NCT01841697 · start 2013-06-13

    Registered record
    Registry ID
    NCT01841697
    Conditions
    Type 2 Diabetes
    Interventions
    Omarigliptin; Sitagliptin; Placebo to omarigliptin; Placebo to Sitagliptin; Open-label Metformin; Open-label Glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06-13
    Completion
    2014-11-17
    Enrolment
    642

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionOmarigliptin; Sitagliptin; Placebo to omarigliptin; Placebo to Sitagliptin +2 more
    PhasePhase 3
    Registry statusCompleted

  • Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

    NCT01879228 · start 2013-06

    Registered record
    Registry ID
    NCT01879228
    Conditions
    Cystic Fibrosis; Pancreatic Insufficiency
    Interventions
    Sitagliptin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-06
    Completion
    2020-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Pancreatic Insufficiency
    InterventionSitagliptin; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

    NCT01709305 · start 2012-11-08

    Registered record
    Registry ID
    NCT01709305
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Metformin; Sitagliptin; Acarbose; Repaglinide; Glimepiride; Gliclazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11-08
    Completion
    2015-04-17
    Enrolment
    5,570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionMetformin; Sitagliptin; Acarbose; Repaglinide +2 more
    PhasePhase 4
    Registry statusCompleted

  • Sitagliptin in Prevention of Type 2 Diabetes Mellitus

    NCT01038648 · start 2011-12

    Registered record
    Registry ID
    NCT01038648
    Conditions
    Type 2 Diabetes
    Interventions
    Sitagliptin; life style modification at base line
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2011-12
    Completion
    2014-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionSitagliptin; life style modification at base line
    PhasePhase 3
    Registry statusWithdrawn